Cancer Research: The Lessons to Learn from COVID-19
- PMID: 32669285
- DOI: 10.1158/2159-8290.CD-20-0823
Cancer Research: The Lessons to Learn from COVID-19
Abstract
The COVID-19 pandemic has caused widespread disruption of cancer clinical trials due to the restrictions on nonessential services and the reallocation of resources, and at the same time the urgent global effort toward discovering therapies that treat or prevent COVID-19 infection has led to shortening of traditional regulatory timelines. This experience should stimulate similar urgency in the way future cancer research is conducted.
©2020 American Association for Cancer Research.
References
-
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. 2020.
-
- Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020.
-
- Release 6.0[cited 2020 Jun 28].
-
- FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency - Guidance for Industry, Investigators, and Institutional Review Boards. 2020.
-
- Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Heal. 2020;2:e286–7.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
